The penetration of aromatase inhibitor into the cerebrospinal fluid and the response in brain/spinal metastases and meningitis of estrogen receptor positive breast cancer

The penetration of aromatase inhibitor into the cerebrospinal fluid and the response in brain/spinal metastases and meningitis of estrogen receptor positive breast cancer - The penetration of aromatase inhibitor into the cerebrospinal fluid and the response in brain/spinal metastases and meningitis of estrogen receptor positive breast cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013789

Enrollment

Registered

2014-04-23

Start date

2014-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain/spinal metastases and meningitis of estrogen receptor positive postmenoposal breast cancer

Interventions

Cerebrospinal fluid examination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Estrogen receptor positive CNS metastatic breast cancer treated with AI

Exclusion criteria

Exclusion criteria: under 20 years old, Performance Status>2

Design outcomes

Primary

Measure	Time frame
Penetration of aromatase inhibitor into the cerebrospinal fluid	—

Secondary

Measure	Time frame
Response to treatment	—

Countries

Japan

Contacts

Public ContactNobuyasu Suganuma

Yokohama City University Surgery

n-suga@vesta.dti.ne.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026